Research programme: dementia therapies - Chase Pharmaceuticals

Drug Profile

Research programme: dementia therapies - Chase Pharmaceuticals

Alternative Names: CPC-252; CPC-260

Latest Information Update: 07 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chase Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia

Most Recent Events

  • 22 Nov 2016 Chase Pharmaceuticals has been acquired by Allergan
  • 19 May 2014 Chase Pharmaceuticals plans a phase I trial of CPC 252 for Alzheimer's disease and dementia associated with Parkinson's disease
  • 12 May 2014 Preclinical trials in Alzheimer's disease in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top